On CNBC’s ‘Mad Money Lightning Round’, Jim Cramer shared his insights on three companies: ADMA Biologics, MP Materials, and Delcath Systems. He expressed cautious optimism about ADMA Biologics, acknowledged the challenges facing MP Materials, and advised against investing in Delcath Systems.